Latest News

09/19/2023

Pfizer Inc. is pleased to announce that the FDA has approved TALZENNA®

08/30/2023

KRAS G12C inhibitor evaluated in NSCLC patients with untreated CNS metastases

08/25/2023

FDA-approval in Multiple Myeloma

08/04/2023

New FDA Approval for Taiho Oncology, Inc

Taiho Oncology, Inc., is pleased to inform you that the “FDA Approves LONSURF® (trifluridine/tipiracil) in Combination With Bevacizumab for Adult Patients With Metastatic Colorectal Cancer (mCRC),” has been issued on Aug. 2, 2023.

12/27/2022

Please join LIBTAYO for a live presentation on the latest data for LIBTAYO

12/15/2022

Mirati announces New Therapy Targeting KRAS G12C Mutation for Metastatic NSCLC.

11/21/2022

LIBTAYO® (cemiplimab-rwlc) is now FDA-approved

10/03/2022

The Eisai Assistance Program

Visit eisaireimbursement.com or call 1-866-61-EISAI (1-866-613-4724)

09/24/2007

NPPES and the NPI Registry

Many of you have noted the recent instability of NPPES and the NPI Registry. CMS has begun implementing changes that should eliminate the instability. We expect that these changes will be completed next week.